Skip to content
The first regenerative therapy targeting OA at its root cause.

Regrowing cartilage.
Restoring movement.
Addressing osteoarthritis.

Stemora is developing the first one-step, disease-modifying therapy designed to regenerate native hyaline cartilage by activating the body's own skeletal stem cells to repair the tissue every other osteoarthritis treatment only masks.

Investor BriefExplore the Science
The Challenge.

OA's pain comes from a deeper source: progressive cartilage loss.

Cartilage cannot heal itself. Today's treatments — from NSAIDs and injections to surgery and joint replacement — only manage pain or mechanically replace the joint. None restore the native hyaline cartilage essential for healthy movement.

500M+
Patients affected globally
Osteoarthritis is the leading cause of disability worldwide and is growing with aging and active populations.
$486B
Annual U.S. healthcare spend
OA is the second most costly condition treated in hospitals, yet current care — injections, surgeries, joint replacements — only manages decline. Patients need something that actually regenerates tissue.
0
FDA-approved regenerative therapies
No approved therapy restores native hyaline cartilage today. Stemora is positioned to be the first.
Track athlete set in the starting blocks before a sprint
The moment care runs out

From the first sharp injury to the inevitable replacement, patients deserve true biological regeneration, not workarounds.

The therapy

One procedure. Native cartilage. Regenerated.

Stemora's therapy harnesses the body's own stem cells to restore true cartilage — naturally. Through a single, minimally invasive procedure, the body's innate repair mechanisms are activated and guided toward regeneration of native hyaline cartilage. No cell harvest. No synthetic implants. No repeat visits.

Step 01

Activate the body's own stem cells

A precise mechanical trigger awakens resident stem cells at the site of injury, initiating the body's natural repair response.

Step 02

Guide regeneration

Targeted biological cues direct these stem cells toward the cartilage lineage, steering them away from scar or bone formation.

Step 03

Restore native cartilage

The result: durable, hyaline cartilage that mirrors the joint's original tissue — not fibrocartilage or synthetic substitutes.

Who we're built for

For everyone who moves with purpose.

From athletes to military operators, weekend warriors to active patients — Stemora helps restore the natural tissue that keeps you moving, performing, and living without limits.

Competitive swimmer underwater in a pool
Peak output
Joints under repeat compression.
Soccer player planting a cleat on the field
Cutting force
Pivot & load.
Athlete stretching her hamstring before training
Sprint mechanics
Stride after stride.
Trail runners navigating uneven terrain
Uneven terrain
Mission tempo.
Military operators descending from a helicopter
Field load
Operational demand.
Lives We Serve

Over half a billion people,
living with joint damage the body can't fully repair.

Global
0M
People living with osteoarthritis
Hundreds of millions worldwide live with daily joint pain and lost mobility — a population growing as we age and stay active longer.
Knee OA
0M
People with knee osteoarthritis
Knee OA is the single largest driver of disability from joint disease — limiting how people walk, work, and play.
Wedge
0M
Patients with focal cartilage defects
Stemora's entry point: patients with focal knee cartilage damage already routed through microfracture — a clear, identifiable population we can reach first.
Team

The minds behind the mechanism.

Stemora brings together leaders in discovery, clinical practice, and therapeutic development — translating regenerative biology into therapies that restore movement and quality of life.

Srujana Cherukuri, PhD
Srujana Cherukuri, PhD
Founder · CEO
Noble Life Sciences · U. Maryland SOM · NIH
Thomas H. Ambrosi, PhD
Thomas H. Ambrosi, PhD
CSO
UC Davis Orthopaedics · Stanford Medicine · DIfE
Matthew P. Murphy, PhD FRCS
Matthew P. Murphy, PhD FRCS
CMO
Manchester · Stanford · MIT TR35 Europe 2023
FAQ

Questions from Patients and investors

For Patients
Not yet. Stemora's therapy is investigational and in preclinical development. It will be evaluated through human clinical trials before it can be offered to patients.
For Investors
Most competitors either install a scaffold or implant, or require a multi-stage cell harvest, expansion, and reimplantation. Stemora is designed as a single outpatient procedure that activates the patient's own biology to regenerate native cartilage — no implant, no cell harvest, no repeat visits.
Stop joint loss. Keep the mission running.

Help us build the first regenerative therapy for OA.

Investor inquiryStrategic partnership